Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide for Atrial Fibrillation Recurrence After Catheter Ablation in Obesity and HFpEF
NCT07630454Phase 4Not yet recruiting
- Sponsor
- Henan Purui Pharmaceutical
- Start
- Aug 2026
- Primary completion
- Aug 2029
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tirzepatide in Atrial fibrillation (AFib) (2 arms), sponsored by Henan Purui Pharmaceutical. Primary endpoint: Recurrence of atrial fibrillation, atrial flutter, or atrial tachycardia. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT07630454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07630454.